Retinalgenix Technologies Stock Performance
| RTGN Stock | USD 3.20 0.00 0.00% |
The company holds a Beta of 0.15, which implies not very significant fluctuations relative to the market. As returns on the market increase, RetinalGenix Technologies' returns are expected to increase less than the market. However, during the bear market, the loss of holding RetinalGenix Technologies is expected to be smaller as well. RetinalGenix Technologies right now holds a risk of 0.0%. Please check RetinalGenix Technologies market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to decide if RetinalGenix Technologies will be following its historical price patterns.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days RetinalGenix Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy technical and fundamental indicators, RetinalGenix Technologies is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
RetinalGenix |
RetinalGenix Technologies Relative Risk vs. Return Landscape
If you would invest 320.00 in RetinalGenix Technologies on November 8, 2025 and sell it today you would earn a total of 0.00 from holding RetinalGenix Technologies or generate 0.0% return on investment over 90 days. RetinalGenix Technologies is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of otc stocks are less volatile than RetinalGenix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RetinalGenix Technologies Target Price Odds to finish over Current Price
The tendency of RetinalGenix OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 3.20 | 90 days | 3.20 | about 56.56 |
Based on a normal probability distribution, the odds of RetinalGenix Technologies to move above the current price in 90 days from now is about 56.56 (This RetinalGenix Technologies probability density function shows the probability of RetinalGenix OTC Stock to fall within a particular range of prices over 90 days) .
RetinalGenix Technologies Price Density |
| Price |
Predictive Modules for RetinalGenix Technologies
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as RetinalGenix Technologies. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.RetinalGenix Technologies Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. RetinalGenix Technologies is not an exception. The market had few large corrections towards the RetinalGenix Technologies' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold RetinalGenix Technologies, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of RetinalGenix Technologies within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.16 | |
β | Beta against Dow Jones | 0.15 | |
σ | Overall volatility | 0.06 | |
Ir | Information ratio | -0.16 |
RetinalGenix Technologies Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of RetinalGenix Technologies for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for RetinalGenix Technologies can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| RetinalGenix Technologies generated a negative expected return over the last 90 days | |
| Net Loss for the year was (2.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RetinalGenix Technologies currently holds about 27 in cash with (1.17 M) of positive cash flow from operations. | |
| Roughly 66.0% of the company outstanding shares are owned by corporate insiders |
RetinalGenix Technologies Fundamentals Growth
RetinalGenix OTC Stock prices reflect investors' perceptions of the future prospects and financial health of RetinalGenix Technologies, and RetinalGenix Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RetinalGenix OTC Stock performance.
| Return On Asset | -49.71 | |||
| Current Valuation | 155.49 M | |||
| Shares Outstanding | 17.27 M | |||
| EBITDA | (2.18 M) | |||
| Cash And Equivalents | 27 | |||
| Total Debt | 114.69 K | |||
| Book Value Per Share | (0.06) X | |||
| Cash Flow From Operations | (1.17 M) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 4.95 K | |||
| Retained Earnings | (8.81 M) | |||
| Current Asset | 11.77 M | |||
| Current Liabilities | 575 K | |||
About RetinalGenix Technologies Performance
By examining RetinalGenix Technologies' fundamental ratios, stakeholders can obtain critical insights into RetinalGenix Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that RetinalGenix Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Retinalgenix Technologies operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about RetinalGenix Technologies performance evaluation
Checking the ongoing alerts about RetinalGenix Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for RetinalGenix Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RetinalGenix Technologies generated a negative expected return over the last 90 days | |
| Net Loss for the year was (2.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RetinalGenix Technologies currently holds about 27 in cash with (1.17 M) of positive cash flow from operations. | |
| Roughly 66.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RetinalGenix Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RetinalGenix Technologies' stock is overvalued or undervalued compared to its peers.
- Examining RetinalGenix Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RetinalGenix Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of RetinalGenix Technologies' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of RetinalGenix Technologies' otc stock. These opinions can provide insight into RetinalGenix Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in RetinalGenix OTC Stock
RetinalGenix Technologies financial ratios help investors to determine whether RetinalGenix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RetinalGenix with respect to the benefits of owning RetinalGenix Technologies security.